JETRO Pavilion at TC Disrupt 2020
JETRO Pavilion at TC Disrupt 2020
Booking Holdings has adapted to people’s desire to stay local amid the pandemic.
AMD is buying Xilinx for $35 billion to give it chip designs it could never have considered before.
Canadian e-commerce company Shopify said on Tuesday it will partner with TikTok to help its one million-plus merchants more easily advertise their products on the video-sharing app, as it looks to grow its customer base. The link-up with Shopify, which provides an e-commerce platform and distribution services to mostly small and medium-sized businesses, comes as a proposal for Walmart Inc to buy a stake in the Chinese-owned firm is stuck in limbo. Shopify said the partnership will allow its merchants to sell product in the form of shoppable video ads, where TikTok users can click on an ad to buy the product.
Avetta launched Avetta Financial Risk™, a tool for evaluating and monitoring the financial health of your supply chain.
The "Global Reverse Osmosis (RO) Membrane Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
* Canadian dollar rises 0.2% against the greenback * Loonie trades in a range of 1.3156 to 1.3212 * Price of U.S. oil increases 0.4% * Canadian bond yields ease across much of a flatter curve TORONTO, Oct 27 (Reuters) - The Canadian dollar strengthened against its U.S. counterpart on Tuesday as stocks and oil prices rose, with the currency rebounding from a 10-day low the day before when a wave of risk aversion swept global markets. Wall Street's main indexes were set to bounce following the benchmark S&P 500's worst day in a month as investors parsed through a deluge of corporate earnings, while bracing for volatility ahead of Election Day. U.S. crude oil futures were up 0.4% at $38.7 a barrel as oil companies shut down some U.S. Gulf of Mexico oil output due to a hurricane, although surging coronavirus infections and rising Libyan supply limited gains.
(Bloomberg) -- The pound looks poised for gains ahead of U.S elections, yet whether it can maintain momentum after the vote is still questionable.Option risk reversals show traders are no longer bearish the U.K. currency over a one-week horizon, opening the way for an advance before the Nov. 3 vote in America. Behind the shift in this gauge of positioning and sentiment lies the latest progress in Brexit negotiations, and a bias in the market to sell the dollar in the run-up to the election.Whether the currency manages to hit fresh highs or sustain gains thereafter, however, still depends largely on how negotiations between the U.K and the European Union pan out. The market’s overall risk appetite given uncertainty surrounding the pandemic will also prove key.The pound was little changed at $1.3031 against the dollar Tuesday, after bouncing back from the psychologically important $1.30 handle early in the session. According to traders in Europe, leveraged funds were fading the move lower, with institutional investors looking to add topside sterling exposure in the options space.Charts are also working in cable’s favor. The currency remains within a bullish trend channel in both the short and medium term. Meanwhile, momentum gauges such as Bloomberg’s fear-and-greed indicator show bulls remain in control of price action.But caution is still warranted. Sterling reached a six-week high of $1.3177 on Oct. 21, only to falter again as profit taking kicked in. Corporate selling on a hedging basis has also been a key element in this pullback, according to a trader in Europe familiar with the transactions who asked not to be identified because he is not authorized to speak publicly.And the outlook further out into the future still remains murky. One-month risk-reversals remain in bearish territory for sterling as investors look for an official resolution in Brexit talks before turning bullish in the longer-term too.According to Bloomberg’s option-pricing model, the chances of the pound trading 5% higher in six months time are slightly higher than the probability of an equivalent drop.NOTE: Vassilis Karamanis is an FX and rates strategist who writes for Bloomberg. The observations he makes are his own and are not intended as investment advice(Updates pound price in fourth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
MultiPlan Corporation (NYSE:MPLN) ("MultiPlan" or the "Company"), a leading value-added provider of data analytics and technology-enabled end-to-end cost management solutions to the U.S. healthcare industry, today announced that its indirect wholly owned subsidiary, MPH Acquisition Holdings LLC (the "Issuer"), upsized and finalized the terms of its offering of $1,300 million in aggregate principal amount of 5.750% Senior Notes due 2028 (the "Notes"). The aggregate principal amount of the Notes to be issued in the offering was increased to $1,300 million from the previously announced $1,200 million. The Notes are expected to be issued by the Issuer and guaranteed on a full and unconditional basis by each of the Issuer’s wholly owned domestic restricted subsidiaries that guarantees the Issuer’s senior secured credit facilities. The offering of the Notes is expected to close on October 29, 2020, subject to customary closing conditions. The Issuer also announced the upsizing of its revolving credit facility from $100 million to $450 million.
Coca-Cola's Australian operation will ditch using polystyrene - an environmental hazard - for its frozen drinks from next year.
Lando Norris apologised to Lewis Hamilton on Tuesday after downplaying the six-time Formula One world champion's record-breaking victory at last weekend's Portuguese Grand Prix.
Helping surgeons to inspect the surgical area for lost sharps.
Churchill Asset Management ("Churchill" or the "Firm"), an investment-specialist affiliate of Nuveen providing customized financing solutions to private equity firms and their portfolio companies, today announced that its flagship levered commingled fund, Churchill Middle Market Senior Loan Fund, received the "Private Debt – Mid-Market Lending" Award at the 2020 AltCredit US Performance Awards. AltCredit Fund Intelligence, a London-based global publication and leading information source on the private debt and credit markets, hosted its annual US Performance Awards in a virtual ceremony on October 21, 2020.
UBS Wealth Management USA announced today that Jessica Guo, Managing Director and Financial Advisor with The Guo Group in Wellesley has been named to Working Mother and SHOOK Research’s list of Top Wealth Advisor Moms, for 2020.
Essentialbobbleheads.com - a Unique way to say Thank You to Essential workers. $5 from each bobblehead goes to Direct Relief to help fight COVID.
Zoom, the video calling company that millions turned to during the pandemic, has finally launched end-to-end encrypted video calls for free accounts. The company said last week that it was readying the feature, months after it drew criticism for denying end-to-end encrypted calls to free users, effectively drawing a line between paid users whose conversations could not be accessed by Zoom and those with free accounts whose conversations weren't as private. Zoom acquired Keybase in May in part to bring its encryption technology to Zoom calls.
TULSA, OK, Oct. 27, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire \-- RJD Green Inc. (OTCPK: RJDG) announced they have completed a letter of intent with a premier mid-west regional fabricator of stone and engineered stone products. The Company, formed in 1995, is a leading regional provider of premium quality natural stone and engineered stone products, with totally automated fabrication systems in place to achieve highest quality control and premium products.The Company combined with the existing Silex Interiors fabrication operations creates over $10,000,000 in annual revenues for the Silex Holdings Division prior to the immediate growth opportunities. Ron Brewer, CEO, stated, “We feel this is a great opportunity to combine two excellent profit centers with symmetrical regional markets. The synergistic operational and administrative opportunities available can offer substantial efficiencies and greater customer outreach. Immediate growth can occur through the planned introduction of new products and services by both operations, which enhance the proficiencies and profitability of the Silex Holdings Division.“RJG Green can now continue its outreach to possible acquisitions in the healthcare sector and green environmental products and services to continue completing its business model.”About Silex Holdings Inc.Silex Holdings is engaged in specialty construction and industrial services sectors and fills a market niche between the Home Depots and local contractors. Silex offers installed stone and engineered stone counter tops, cabinets and related products for the residential builders, commercial projects, remodel contractors, and retail customers on a regional basis.About RJD Green, Inc.The Company operates as a holding company with a focus of acquiring and managing assets and companies. RJD Green operates in three divisions: RJD Green Healthcare Services Division, which owns IOSoft Inc., a company that provides discrete payment technologies, services and software that can be integrated into targeted offerings for healthcare provider networks, hospitals, healthcare payers and individual providers; Earthlinc Environmental Services Division, which provides green environmental services and technologies; and Silex Holdings Division, which is focused in specialty construction and industrial services. The initial operations, Silex Interiors, fills a market niche between the Home Depots and local contractors. Silex manufactures and installs granite/other counter tops, cabinets and related products to the residential builder, commercial contractor, remodel contractor and DIY customer. Forward-looking Statement: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events of future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluation such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.Company Contact: RJD Green, Inc. Ron Brewer, CEO 918.551.7883 email@example.comCompany Publicist:Kenneth Quist918.firstname.lastname@example.org
As part of the deal, Waymo will provide its automated-driving technology to Daimler's Freightliner Cascadia brand of Class 8 trucks. The autonomous Freightliner Cascadia trucks would be available to customers in the United States in the "coming years", the companies said, adding that they plan to explore the expansion of the self-driving technology globally in the "near future".
Baptist Health engages Kyruus to elevate the digital access experience for consumers in Kentucky, Illinois, Indiana and Tennessee.
* 5,500 volunteers enrolled to date in pivotal Phase 3 clinical trial in the U.K. * Study expanded to 15,000 participants * Full enrollment expected by end of November * Event-driven interim data expected as soon as early first quarter 2021 * U.S. pivotal Phase 3 clinical trial planned to begin by end of November * Significant progress in large-scale manufacturing achieved with some delay from original timeline * Company to present data from its ongoing Phase 1/2 clinical trial, including new Phase 2 reactogenicity data, during public CDC Advisory Committee on Immunization Practices (ACIP) meeting on October 30 GAITHERSBURG, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19 vaccine candidate. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant. The Company also announced that it will present data from its ongoing Phase 1/2 clinical trial, including new Phase 2 reactogenicity data, on Friday, October 30 during the United States (U.S.) Center for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices’ (ACIP) meeting.U.K. Phase 3 Clinical Trial UpdateNovavax has enrolled over 5,500 participants to date in the United Kingdom (U.K.) trial, which it has expanded to 15,000 volunteers. The increased enrollment is likely to facilitate assessment of safety and efficacy in a shorter time period. Novavax expects this trial to be fully enrolled by the end of November, and dependent on the overall COVID-19 attack rate, interim data in this event-driven trial are expected as soon as early first quarter 2021. These data are expected to serve as the basis for global licensure.“We are pleased with the significant progress made in our Phase 3 clinical trial since it began in the United Kingdom at the end of September,” said Gregory M. Glenn, M.D., President of Research and Development at Novavax. “We are grateful for the support of the U.K. Government’s Vaccines Taskforce (VTF) and the National Institute for Health Research (NIHR) for our pivotal trial. Recognizing the recent, large increase in the number of COVID-19 cases in the U.K., as well as the rapid progress in participant enrollment for our trial, in consultation with the VTF and NIHR, we adjusted our plans and increased enrollment.”In alignment with Novavax’ commitment to transparency, the Company has posted the protocol for this trial on its website at https://www.novavax.com/resourcesprotocols.U.S. Phase 3 Clinical Trial UpdateNovavax currently expects the pivotal clinical trial to begin in the United States and Mexico by the end of November. The Company has made significant progress in large-scale manufacturing, with delays experienced versus original timing estimates.Novavax has been developing large-scale manufacturing processes at multiple sites around the world and plans to use production from its contract manufacturing site at FUJIFILM Diosynth Biotechnologies’ Morrisville, North Carolina site in this Phase 3 clinical trial.Additional Phase 3 Clinical Trial InformationUnited Kingdom Novavax’ first pivotal Phase 3 clinical trial, begun in September in partnership with the U.K. Government’s Vaccines Taskforce, will be expanded from 10,000 to 15,000 volunteers, some of whom have been recruited through the National Health Service (NHS) Vaccine Registry. The trial protocol calls for unblinding of data once 152 participants have achieved mild, moderate or severe endpoints. Two interim analyses are planned once 66 and 110 endpoints have occurred.United States/Mexico Novavax’ pivotal Phase 3 clinical trial is being conducted with support from the U.S. Government through Operation Warp Speed. The trial design is harmonized with those of other leading companies, and calls for the enrollment of up to 30,000 participants in the U.S. and Mexico, with proportional representation among diverse populations most vulnerable to COVID-19 distributed across race/ethnicity, age and those living with co-morbidities. The trial protocol will be posted on Novavax’ website upon initiation.ACIP Presentation Friday, October 30Novavax’ Senior Vice President and Chief Medical Officer, Filip Dubovsky, M.D., will present an update during a public meeting of the CDC’s ACIP between 10:00 am and 12:30 am ET on Friday, October 30. For more information, please visit www.cdc.gov/vaccines/acip/meetings/index.html.About NVX-CoV2373 NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and cannot replicate, nor can it cause COVID-19. In preclinical trials, NVX-CoV2373 demonstrated induction of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. In the Phase 1 portion of its Phase 1/2 clinical trial, NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. NVX-CoV2373 is also being evaluated in a Phase 3 trial in the U.K. and two ongoing Phase 2 studies that began in August; a Phase 2b trial in South Africa, and a Phase 1/2 continuation in the U.S. and Australia. Novavax has secured $2 billion in funding for its global coronavirus vaccine program, including up to $388 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI).About Novavax Novavax, Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is undertaking clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.Novavax Forward Looking Statements Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, and Quarterly Report on Form 10-Q for the period ended June 30, 2020, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.Contacts: Investors Erika Trahan email@example.com 240-268-2022Media Brandzone/KOGS Communication Edna Kaplan firstname.lastname@example.org 617-974-8659
Dublin, Oct. 27, 2020 (GLOBE NEWSWIRE) -- The "Foot Orthotic Insoles Market Forecast to 2027 Covid-19 Impact and Global Analysis By Product Type; Material; Application; Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering. According to this report the global foot orthotic insoles market is expected to reach US$ 5,464.57 million by 2027 from US$ 3,560.00 million in 2019; it is estimated to grow at a CAGR of 5.7% from 2020 to 2027. The report highlights the trends prevailing in the global foot orthotic insoles market, and the drivers and deterrents pertaining to its growth. Based on product type, the foot orthotic insoles market is segmented into customized and prefabricated. The customized segment held the largest share of the market in 2019, whereas the same segment is anticipated to register the highest CAGR of 6.0% in the market during the forecast period. The rising healthcare spending worldwide and aging population mostly drives the growing demand for customized foot insoles market. For instance, the number of people aged 65 or older increased by 1.6 million from 2014 to 2015, as per the U.S. Census Bureau. The foot orthotic insoles market growth is also attributed to the increasing incidence of diabetes, arthritis, and other foot conditions and growing demand from sports sector .However, lack of adoption in emerging economies is likely to hamper the growth of the market during the forecast period. Aetrex Worldwide, Inc, Bauerfeind AG, OttoBock, Superfeet Worldwide Inc., Sidas, Algeos, Amfit Inc, Arden Orthotics, Acor Orthopaedic, Inc. and YELLOW WOOD PARTNERS, LLC are among others are the prominent players operating in the foot orthotic insoles market. The key companies are focused on organic strategies to sustain their position in the market. For instance, in Jul-2019, Yellow Wood Partners and Bayer announced that the company has entered into a definitive agreement to buy the Dr. Scholl's business from Bayer for a purchase price of 585 million U.S. dollars. Reasons to Buy * Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the foot orthotic insoles market. * Highlights key business priorities in order to assist companies to realign their business strategies. * The key findings and recommendations highlight crucial progressive industry trends in the global foot orthotic insoles market, thereby allowing players across the value chain to develop effective long-term strategies. * Develop/modify business expansion plans by using substantial growth offering developed and emerging markets. * Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it. * Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution. Key Topics Covered: 1\. Introduction 2\. Foot Orthotic Insoles Market - Key Takeaways 3\. Research Methodology 3.1 Coverage 3.2 Secondary Research 3.3 Primary Research 4\. Foot Orthotic Insoles Market - Market Landscape 4.1 Overview 4.2 PEST Analysis 4.2.1 North America - PEST Analysis 4.2.2 Europe - PEST Analysis 4.2.3 Asia-Pacific - PEST Analysis 4.2.4 Middle East and Africa (MEA) - PEST Analysis 4.2.5 South & Central America - PEST Analysis 4.3 Expert Opinion 5\. Foot Orthotic Insoles Market- Key Market Dynamics 5.1 Market Drivers 5.1.1 Increasing Incidence of Diabetes, Arthritis, and Other Foot Conditions 5.1.2 Growing Demand from Sports Sector 5.2 Market Restraints 5.2.1 Lack of Adoption in Emerging Economies 5.3 Market Opportunities 5.3.1 Increase in Adoption of Digital Platforms 5.4 Future Trends 5.4.1 3D Printed Orthotics Insoles 5.5 Impact Analysis 6\. Foot Orthotic Insoles Market - Global Analysis 6.1 Global Foot Orthotic Insoles Market Revenue Forecast And Analysis 6.2 Global Foot Orthotic Insoles Market, By Geography - Forecast And Analysis 6.3 Market Positioning of Key Players 7\. Foot Orthotic Insoles Market Analysis - By Product Type 7.1 Overview 7.2 Foot Orthotic Insoles Market Revenue Share, by Foot Orthotic Insoles by Product Type (2019 and 2027) 7.3 Customized 7.3.1 Overview 7.3.2 Customized: Foot Orthotic Insoles Market - Revenue and Forecast to 2027 (US$ Million) 7.4 Prefabricated 7.4.1 Overview 7.4.2 Prefabricated: Foot Orthotic Insoles Market - Revenue and Forecast to 2027 (US$ Million) 8\. Foot Orthotic Insoles Market Analysis - By Material 8.1 Overview 8.2 Foot Orthotic Insoles Market Revenue Share, by Material (2019 and 2027) 8.3 Thermoplastics 8.3.1 Overview 8.3.2 Thermoplastics: Foot Orthotic Insoles Market - Revenue and Forecast to 2027 (US$ Million) 8.4 Leather 8.4.1 Overview 8.4.2 Leather: Foot Orthotic Insoles Market - Revenue and Forecast to 2027 (US$ Million) 8.5 Composite Carbon Fibers 8.5.1 Overview 8.5.2 Composite Carbon Fibers: Foot Orthotic Insoles Market - Revenue and Forecast to 2027 (US$ Million) 8.6 Polyethylene Foams 8.6.1 Overview 8.6.2 Polyethylene Foams: Foot Orthotic Insoles Market - Revenue and Forecast to 2027 (US$ Million) 8.7 Cork 8.7.1 Overview 8.7.2 Cork: Foot Orthotic Insoles Market - Revenue and Forecast to 2027 (US$ Million) 8.8 Ethyl-Vinyl Acetates (EVAs) 8.8.1 Overview 8.8.2 Ethyl-Vinyl Acetates (EVAs): Foot Orthotic Insoles Market - Revenue and Forecast to 2027 (US$ Million) 8.9 Gel 8.9.1 Overview 8.9.2 Gel: Foot Orthotic Insoles Market - Revenue and Forecast to 2027 (US$ Million) 8.10 Others 8.10.1 Overview 8.10.2 Others: Foot Orthotic Insoles Market - Revenue and Forecast to 2027 (US$ Million) 9\. Foot Orthotic Insoles Market Analysis - By Application 9.1 Overview 9.2 Foot Orthotic Insoles Market Revenue Share, by Application (2019 and 2027) 9.3 Sports and Athletics 9.3.1 Overview 9.3.2 Sports and Athletics: Foot Orthotic Insoles Market - Revenue and Forecast to 2027 (US$ Million) 9.4 Medical 9.4.1 Overview 9.4.2 Medical: Foot Orthotic Insoles Market - Revenue and Forecast to 2027 (US$ Million) 9.5 Personal Comfort 9.5.1 Overview 9.5.2 Personal Comfort: Foot Orthotic Insoles Market - Revenue and Forecast to 2027 (US$ Million) 10\. Foot Orthotic Insoles Market Analysis - By Distribution Channel 10.1 Overview 10.2 Foot Orthotic Insoles Market Share, by Distribution Channel, 2019 and 2027, (%) 10.3 Drug Stores 10.3.1 Overview 10.3.2 Drug Stores: Foot Orthotic Insoles Market - Revenue and Forecast to 2027 (US$ Million) 10.4 Hospitals and Specialty Clinics 10.4.1 Overview 10.4.2 Hospitals and Specialty Clinics: Foot Orthotic Insoles Market - Revenue and Forecast to 2027 (US$ Million) 10.5 Online Stores 10.5.1 Overview 10.5.2 Online Stores Segment : Foot Orthotic Insoles Market - Revenue and Forecast to 2027 (US$ Million) 10.6 Others 10.6.1 Overview 10.6.2 Others Segment : Foot Orthotic Insoles Market - Revenue and Forecast to 2027 (US$ Million) 11\. Foot Orthotic Insoles Market - Geographic Analysis 11.1 North America: Foot Orthotic Insoles Market 11.2 Europe: Foot Orthotic Insoles Market 11.3 Asia Pacific: Foot Orthotic Insoles Market 11.4 Middle East and Africa: Foot Orthotic Insoles Market 11.5 South and Central America: Foot Orthotic Insoles Market 12\. Impact of COVID-19 Pandemic on Global Foot Orthotic Insoles Market 12.1 North America: Impact Assessment of COVID-19 Pandemic 12.2 Europe: Impact Assessment of COVID-19 Pandemic 12.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic 12.4 Rest of the World: Impact Assessment of COVID-19 Pandemic 13\. Foot Orthotic Insoles Market - Industry Landscape 13.1 Overview 13.2 Growth Strategies Done by the Companies in the Market, (%) 13.3 Organic Developments 13.3.1 Overview 13.4 Inorganic Developments 13.4.1 Overview 14\. Company Profiles 14.1 SIDAS 14.1.1 Key Facts 14.1.2 Business Description 14.1.3 Products and Services 14.1.4 Financial Overview 14.1.5 SWOT Analysis 14.1.6 Key Developments 14.2 OTTOBOCK 14.2.1 Key Facts 14.2.2 Business Description 14.2.3 Products and Services 14.2.4 Financial Overview 14.2.5 SWOT Analysis 14.2.6 Key Developments 14.3 Aetrex Worldwide, Inc. 14.3.1 Key Facts 14.3.2 Business Description 14.3.3 Products and Services 14.3.4 Financial Overview 14.3.5 SWOT Analysis 14.3.6 Key Developments 14.4 Algeos 14.4.1 Key Facts 14.4.2 Business Description 14.4.3 Products and Services 14.4.4 Financial Overview 14.4.5 SWOT Analysis 14.4.6 Key Developments 14.5 Amfit Inc. 14.5.1 Key Facts 14.5.2 Business Description 14.5.3 Products and Services 14.5.4 Financial Overview 14.5.5 SWOT Analysis 14.5.6 Key Developments 14.6 Arden Orthotics 14.6.1 Key Facts 14.6.2 Business Description 14.6.3 Products and Services 14.6.4 Financial Overview 14.6.5 SWOT Analysis 14.6.6 Key Developments 14.7 Superfeet Worldwide Inc. 14.7.1 Key Facts 14.7.2 Business Description 14.7.3 Products and Services 14.7.4 Financial Overview 14.7.5 SWOT Analysis 14.7.6 Key Developments 14.8 Bauerfeind 14.8.1 Key Facts 14.8.2 Business Description 14.8.3 Products and Services 14.8.4 Financial Overview 14.8.5 SWOT Analysis 14.8.6 Key Developments 14.9 YELLOW WOOD PARTNERS, LLC. 14.9.1 Key Facts 14.9.2 Business Description 14.9.3 Products and Services 14.9.4 Financial Overview 14.9.5 SWOT Analysis 14.9.6 Key Developments 14.10 Acor Orthopaedic, Inc. 14.10.1 Key Facts 14.10.2 Business Description 14.10.3 Products and Services 14.10.4 Financial Overview 14.10.5 SWOT Analysis 14.10.6 Key Developments 15\. Appendix 15.1 About the Publisher 15.2 Glossary of Terms For more information about this report visit https://www.researchandmarkets.com/r/f40yl6Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900